It's time to apply for trading two new promising IPO's of biotech companies. Pandion Therapeutics and Berkeley Lights are launching their IPO's on July 16, with 35% ans 34% yield potential, respectively.
Pandion Therapeutics, a US based company that focuses on developing new methods of autoimmune disease treatment, is launching its IPO in the NASDAQ on July 16. The company's platform enables using a new approach to creating immune response modifiers for the nerve endings. Immune response modifiers are biologically active agents that impact the immune system and take part in its functioning.
The company's flagship product, a medical drug against ulcerative colitis and other inflammatory diseases, is currently undergoing the first stage of clinical trials. Pandion Therapeutics is also developing PT627, a drug for rheumatoid arthritis, diabetes, and other autoimmune diseases treatment. The clinical trials are scheduled for 2021. Meanwhile, the sales of PT101, the flagship drug, may start as early as in 2026.
As of March 31, 2020, the company had $67,658M in cash on its balance sheet. To date, Pandion Therapeutics raised $138M, its largest pre-IPO shareholders being Versant Venture Capital, Polaris Partners, Roche Finance Ltd, among others.
In 2018, the ulcerative colitis treatment market was worth around $6.79B, while in 2027 it is expected to rise by 50% due to the new treatment methods focusing on symptom control and large gut healing process.
Pandion Therapeutics IPO: Key Facts
● Yield potential: 35%
● IPO Date: July 16
● Exchange: NASDAQ (trading as PAND)
● IPO Size: 5.5M shares
● Starting Price: $16 to $18
● Underwriters: Goldman Sachs, Morgan Stanley, SVB Leerink, BMO Capital Markets
● Earnings in Q1 2020: $2M
● EBIT in Q1 2020: -$7M
● Net profit in Q1 2020: -$6M
● Net Debt: $0
The company is expected to raise $93.5M with the IPO, which is to be invested into further research and business purposes.
You can Apply to trade Pandion Therapeutics IPO until 7 pm (UTC+2), July 15. In order to trade, you need an investment account with Freedom Finance.
Trade PAND IPO
Berkeley Lights is launching its IPO in the NASDAQ on July 16. This is a US based company that created a platform, thanks to which its users can create and release cell based products faster.
Such products are used in many medical domains, such as ophthalmology, cancer treatment, CVD and GIT diseases treatment, and more. In order for this treatment to be efficient, though, high precision is required. Millions of cells have to be analyzed and much cash to be spent before a drug is developed. Berkeley Lights platform speeds this process up, translating the biological information into the digital one, which reduces operational costs. Berkeley Lights has proprietary software for analysis and patented wearable parts.
As of December 31, 2019, Berkeley's customer base included 45 companies, such as Pfizer, Novartis, Sanofi, Shire, Teva Pharmaceuticals, and other large names of the biopharma world. To date, Berkeley Lights has raised $208.50M, the largest pre-IPO shareholders being WRVI Capital and Sequoia Capital.
According to MarketsAndMarkets, the cell analysis global market was worth $16B in 2019. By 2024, it may reach $22.70. The major growth drivers are the rising government R&D financing and the increasing number of chronic and infective disease incidents. Berkeley Lights already has a working platform and large enterprise level customers, which means the company also has god chances for growth.
Read More on Berkeley Lights IPO
● Yield potential: 34%
● IPO Date: July 16
● Exchange: NASDAQ (trading as BLI)
● IPO Size: 7.4M shares
● Starting Price: $16-$18
● Underwriters: J.P. Morgan, Morgan Stanley, Cowen
● Earnings in Q1 2020: $14M
● EBIT in Q1 FY2020: -$7M
● Net profit in Q1 2020: -$8M
● Net Debt: $0M
The company is expected to raise around $125M with the IPO, which are to be invested into platform development and the business needs.
You can apply to trade the Berkeley Lights IPO before Jule 15, 7:00 pm (UTC+2). In order to trade, you need an investment account with Freedom Finance.
Trade BLI IPO
*Investment in stocks and other financial instruments may result in loss of capital. Past investment results do not guarantee future returns. The forecasts are not reliable indicator of future performance.